Moreover, patients with high TNFSF10 expression usually exhibited a good response to chemotherapy [41], while TNFRSF4 was associated with chemosensitivity and good prognosis in ovarian cancer patients [42], and IRF7 was upregulated in patients in the chemotherapy responsive group [43]. This evidence concerns the gene IRF7 and ovarian carcinoma.